Search Medical Condition
Please enter condition
Please choose location

Pasadena, California Clinical Trials

A listing of Pasadena, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (610) clinical trials

Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial

The PORTICO trial will include approximately 758 randomized subjects at up to 70 investigational sites. The study is powered to analyze the high risk cohort and extreme risk cohort together against a commercially available control for the primary safety and effectiveness endpoints. In addition, data for each cohort will be ...

Phase N/A

0.0 miles

Learn More »

Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination

This multicenter screening study will be conducted in order to determine a subject's tumor antigen expression profile and HLA subtype, and subsequent eligibility for Adaptimmune sponsored clinical treatment trials studying the safety and efficacy of autologous genetically modified T-cells engineered with enhanced TCRs targeting specific antigens. No treatment intervention will ...

Phase N/A

0.32 miles

Learn More »

Prospective Randomized On-X Versus SJM Evaluation Trial

The study is a multi-centre, randomized trial that will sequentially enroll up to 500 eligible patients in each group from up to 10 participating study centres internationally to test the hypothesis.

Phase N/A

0.32 miles

Learn More »

Eliminate Thromboembolism: Improving Anticoagulation in Non-valvular Atrial Fibrillation Patients

ELITE will be a prospective, multicenter observational study of 500 participants to characterize demographics, comorbidities, risk profiles, socioeconomic status, and patient preferences related to anticoagulation management. The primary study endpoint will be warfarin discontinuation without resumption as documented in the medical record. Secondary outcomes of interest include warfarin adherence and ...

Phase N/A

1.38 miles

Learn More »

Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas

PRIMARY OBJECTIVES: I. To determine the activity of a smoothened, frizzled class receptor (SMO) and PTCH1 inhibitor in patients with meningiomas harboring SMO mutations as measured by 6-month progression free survival (PFS) and response rate. II. To determine the activity of a FAK inhibitor in patients with meningiomas harboring neurofibromin ...

Phase

1.38 miles

Learn More »